CRISPR Therapies in 2026: What Is Approved and What Remains Experimental

CRISPR has crossed a historic boundary: a therapy using genome editing is authorised for serious blood disorders. But the phrase “molecular scissors” hides a complex clinical procedure. Cells are collected, modified in a laboratory, checked and returned after intensive preparation.

What is approved

Casgevy, also called exagamglogene autotemcel or exa-cel, uses CRISPR/Cas9 on a patient's blood stem cells. Rather than directly repairing the sickle-cell mutation, it disrupts a regulatory region to restore foetal haemoglobin, which helps prevent red blood cells taking their abnormal shape.

The FDA authorised Casgevy in late 2023 for certain patients with sickle cell disease, and in July 2026 announced an expansion to young children in the US indication. The European Union also has a conditional authorisation for defined cases of sickle cell disease and transfusion-dependent beta thalassaemia.

An authorisation is specific to a country, age, indication and qualified centre. It does not mean every person with the disease can receive treatment immediately.

Why treatment remains demanding

Stem cells are mobilised and collected. They are edited outside the body, then the patient receives myeloablative conditioning to make room in the marrow. This chemotherapy can cause infection, infertility and other serious complications. Hospitalisation, laboratory coordination and follow-up are substantial.

Benefit may be major for a disease that causes pain, organ damage and hospitalisation. The decision still requires a specialist team to compare procedure risk, alternatives and the individual situation.

Ex vivo and in vivo

Casgevy is ex vivo editing: cells leave the body, allowing quality checks before return. In vivo editing delivers the tool directly into an organ. It could simplify some treatments, but delivery, dose, immune response and off-target changes become harder to control.

In-vivo studies in the liver, eye or other tissues remain trials until a regulator has reviewed a complete application. A lower biomarker is not automatically durable clinical improvement.

Off-target changes

CRISPR must cut in the intended place. Developers look for unintended edits, chromosome abnormalities and whether cells behave normally. No assay proves zero risk; long-term follow-up aims to detect rare or delayed events.

EMA describes extended registry follow-up, and gene therapies receive specific surveillance. Duration matters because edited cells may persist for years.

Why CRISPR is not universal

A disorder driven by one accessible mechanism is simpler than cancer, Alzheimer's disease or ageing, which involve many genes, cells and environmental factors. The editor also has to reach the correct tissue without affecting others. Biology, not only tool precision, sets the difficulty.

Price and specialist-centre capacity will also limit access. A potentially one-time therapy may prevent years of care, but still requires personalised manufacturing, hospital treatment and monitoring.

The verdict

CRISPR is no longer only a laboratory promise: it has produced a regulator-authorised therapy with substantial benefits for selected patients. That success validates one method, not every claim about correcting disease or rejuvenation.

The next milestones are making ex-vivo treatment less burdensome and proving that in-vivo editing delivers durable benefit at acceptable risk. For another medical frontier where evidence advances step by step, read our 2026 cancer-medicine dossier.